The Quantellect read.As of Nov 19, 2026, 7 active firms cover Rocket Pharmaceuticals Inc: 5 rate it Buy or better, 2 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. The target range is very wide, $4.00 to $15.00 (about 3.8x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $8.86 sits 319% above the current $2.12. Sentiment has drifted a little more constructive lately, with Sell ratings easing from 2 to 0 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.41 next quarter toward $-1.58 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 active firms
Buy
Strong Buy00%
Buy571%
Neutral229%
Sell00%
Strong Sell00%
Based on 7 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$8.86
+318.8% upside
Average target across 7 active firms as of Nov 19, 2026 vs $2.12 current
Highest Target$15.00
Average Target$8.86
Lowest Target$4.00
Detailed analyst forecasts for RCKT
Showing 1–8 of 8 named analysts shown · 7 active firms in the rating projection
As of Nov 19, 2026, 5 of 7 active firms rate RCKT a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
RCKT EPS & revenue forecast
EPS · NEXT QUARTER
$-0.41
Range $-0.47 – $-0.31 · 3 analysts · -2% YoY
Next period, 3 analysts expect Rocket Pharmaceuticals Inc to earn $-0.41 a share (range $-0.47 – $-0.31), versus $-0.42 a year earlier. Full-year consensus is $-0.12, growing to $-1.58 the year after.
REVENUE · NEXT QUARTER
$2.4M
Range $0 – $4.5M · 3 analysts
Revenue is expected to reach $2.4M (range $0 – $4.5M). Full-year consensus is $753.4K, rising to $12.0M next year.
Top analysts covering Rocket Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on RCKT.
#1
Geulah Livshits
Chardan Capital · Rank #104
Buy
$11.00+420.1% to target
Overall win rate
43%
+ Follow
#2
Keay Nakae
Chardan Capital · Rank #130
Buy
$11.00+420.1% to target
Overall win rate
41%
+ Follow
#3
Josh Schimmer
Cantor Fitzgerald · Rank #132
Buy
$10.00+372.8% to target
Overall win rate
44%
+ Follow
#4
Greg Harrison
Scotiabank · Rank #223
Buy
$19.00+798.3% to target
Overall win rate
38%
+ Follow
#5
WI
Whitney Ijem
Canaccord Genuity · Rank #392
Buy
$10.00+372.8% to target
Overall win rate
35%
+ Follow
RCKT stock forecast FAQ
What is RCKT's average 12-month price target?+
The 7 active firms with a live target average $8.86 for Rocket Pharmaceuticals Inc over the next 12 months, ranging from a $15.00 high to a $4.00 low, as of Nov 19, 2026.
Is RCKT stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 7 active firms as of Nov 19, 2026, 5 rate it Buy or Strong Buy, 2 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for RCKT?+
The Street-high target is $15.00 (Wedbush), and the Street-low is $4.00 (Goldman Sachs). The average of all 7 active-firm targets is $8.86.
How many active Wall Street firms cover RCKT?+
7 active firms have a recognized rating on Rocket Pharmaceuticals Inc as of Nov 19, 2026, and 7 active firms carry a live 12-month price target.
Who is the most accurate analyst covering RCKT?+
Among analysts who currently cover RCKT, Geulah Livshits of Chardan Capital has the strongest overall Quantellect track record (Rank #104). Their current call is Buy with a $11.00 target.
What is Rocket Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-0.41 per share (range $-0.47 – $-0.31) across 3 analysts. Full-year EPS is projected at $-0.12, rising to $-1.58 the following year.
How much revenue is Rocket Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $2.4M (range $0 – $4.5M). Full-year revenue is projected at $753.4K, growing to $12.0M next year.
Have analysts been upgrading or downgrading RCKT lately?+
As of Nov 19, 2026, 5 of 7 active firms rate RCKT a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their RCKT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.